The South Korean Ministry of Food and Drug Safety has approved the country’s first AI-based medical software, ACRYL-001, for diagnosing depression. This advanced tool, developed by Acryl, uses artificial intelligence to analyze patient interviews. It then provides a probability score to help doctors determine the likelihood of depression.
ACRYL-001 aims to improve the accuracy of diagnosing depression and make the assessment process faster. By using AI, it can analyze patterns in a patient’s responses that might be difficult for a human to detect. This can assist healthcare professionals in making better-informed decisions and providing timely support to patients.
This approval is a big step for South Korea in combining artificial intelligence with mental healthcare. It highlights how technology can be used to address mental health challenges and improve patient care. ACRYL-001 sets the stage for further advancements in AI-driven medical tools, making mental health assessments more accessible and efficient.
